TNFRSF17 and Miyoshi myopathy: MCARH109, a novel CAR T cell construct targeting GPRC5D, showed promising efficacy in a phase 1 trial in patients with heavily treated recurrent or refractory MM, even in those who had previously progressed on BCMA‐targeted therapy.